Bryan

Bryan

Prostate Cancer

At just 45 years old, Bryan received news that would change his life forever. What started as a routine visit to his urologist in May 2023 for frequent urination quickly escalated into a life-altering diagnosis. Bryan’s PSA levels, which can indicate higher risk for prostate cancer, were in the hundreds—far above the normal range of 0–5. A full-body scan revealed cancer in the prostate, lymph nodes nearby, and a small spot on his hip.

The diagnosis was a shock to Bryan and his wife. An avid skateboarder and cyclist, Bryan had always led an active lifestyle. Bryan immediately sought care at Texas Oncology under the care of Dr. Mike Lattanzi, Executive Member of the Genitourinary Cancer Research Executive Committee through SCRI at Texas Oncology. “He met me during a time of confusion and hard decisions with the reassuring words, ‘You’re in good hands,’” said Bryan.

Bryan’s mother passed away from ovarian cancer in 2021, and years earlier, she had undergone genetic testing that revealed a BRCA gene mutation. She had also battled breast cancer two decades prior. At Dr. Lattanzi’s recommendation, Bryan immediately underwent genetic testing and confirmed he carries the same BRCA mutation as his mother. He’s encouraged his 21-year-old son to get tested as well, understanding the importance of early detection and awareness.

A history of ovarian cancer on the maternal side can signal an increased risk of prostate cancer in men, due to inherited genetic mutations such as BRCA1 and BRCA2 which, for men, can impact prostate cancer risk - often at a younger age and with more aggressive disease characteristics. Understanding this genetic link is crucial for early screening and personalized care. The advice from his mother to pursue genetic testing always lingered in Bryan’s mind, and though he initially pushed it aside, he now says, “Moms are always right.”

Bryan began radiation therapy in October 2023 which included 45 treatments over nine weeks, targeting the midsection and hip. Though painless, the process was uncomfortable as it required a full bladder for each session. He also underwent laser surgery in December 2024, which he describes as painless and efficient.

Due to Bryan’s BRCA mutation, he was eligible for a clinical trial testing a class of medicines called PARP inhibitors to treat men with advanced prostate cancer associated with BRCA and other similar genetic changes.  Bryan enrolled in a global phase III clinical trial through Sarah Cannon Research Institute (SCRI) at Texas Oncology in May 2023. The results were remarkable: his PSA levels dropped rapidly and have remained undetectable for more than a year. He experienced no side effects and continues to take six daily pills as part of the trial. His treatment has evolved from monthly visits and blood draws to quarterly check-ins, reflecting his stable progress.

Despite the challenges, Bryan has maintained a positive outlook. He credits the incredible support from his care team, especially Dr. Lattanzi, whose compassion extends beyond the clinic—Bryan even recently ran into him and his family at a local BBQ spot which made for a happy reunion outside of the clinical setting. “Everybody has been amazing and so positive,” Bryan says. “It’s the way I like to live, and it’s kept my attitude strong.”

Working from home has given Bryan the flexibility to prioritize his health while remaining active and fully engaged in his career throughout his cancer journey. He continues to ride his bike, walk his dogs twice a day, play on an adult sand volleyball team, and spend quality time with his family.

Bryan’s journey is a testament to the power of early detection, personalized care, and the strength of a positive mindset. Through the support of SCRI at Texas Oncology and his medical team, he’s not just surviving—he’s thriving.